LACTOBACILLUS REUTERI ( DrugBank: Lactobacillus reuteri )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
97潰瘍性大腸炎3
299嚢胞性線維症1

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05118919
(ClinicalTrials.gov)
February 9, 202226/10/2021A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative ColitisA Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative ColitisUlcerative ColitisBiological: BGP-014;Biological: PlaceboBioGaia Pharma ABNULLRecruiting18 YearsN/AAll50Phase 1/Phase 2Sweden
2EUCTR2019-004578-25-SE
(EUCTR)
09/07/202127/12/2019A clinical study in patients with mild to moderate ulcerative colitis to test the tolerability of Lactobacillus reuteri BGP-014A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis Mild to moderate ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Name: BGP-014 Capsules
Product Code: BGP-014
INN or Proposed INN: Lactobacillus reuteri
Other descriptive name: LACTOBACILLUS REUTERI
BioGaia Pharma ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 1;Phase 2Sweden
3NCT03798210
(ClinicalTrials.gov)
January 1, 20177/1/2019Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative ColitisThe Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative ColitisUlcerative Colitis FlareDietary Supplement: Lactobacillus reuteri;Dietary Supplement: PlaceboUppsala UniversityNULLRecruiting18 Years80 YearsAll40Phase 2Sweden

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01737983
(ClinicalTrials.gov)
May 200912/7/2012Effect of Lactobacillus Reuteri in Cystic FibrosisLactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.CYSTIC FIBROSISDietary Supplement: Lactobacillus reuteri;Dietary Supplement: placeboAzienda Policlinico Umberto INULLCompleted6 Years42 YearsBoth61Phase 4Italy